Intervention not reported
Pain VAS (0 to 100) Short‐term · patients with non‐specific chronic low back pain
1 finding from 1 review
Intervention not reported
Disability Multiple scales (0 to 100) Short‐term · patients with non‐specific chronic low back pain
1 finding from 1 review
Intervention not reported
Pain VAS (0 to 100) Short‐term · patients with non‐specific chronic low back pain
1 finding from 1 review
Intervention not reported
Disability Multiple scales (0 to 100) Short‐term · patients with non‐specific chronic low back pain
1 finding from 1 review
Intervention not reported
Pain VAS (0 to 100) Short‐term · patients with non‐specific chronic low back pain
1 finding from 1 review
Intervention not reported
Disability Multiple scales (0 to 100) Short‐term · patients with non‐specific chronic low back pain
1 finding from 1 review
Intervention not reported
Disability Multiple scales (0 to 100) Short‐term · patients with non‐specific chronic low back pain
1 finding from 1 review
Intervention not reported
Pain VAS (0 to 100) Short‐term · patients with non‐specific chronic low back pain
1 finding from 1 review
Global state: not improved ‐ short‐term GAF · patients with schizophrenia
CHLORPROMAZINE may leads to lower global state: Not improved (short term) compared with RESERPINE (low certainty).
1 finding from 1 review
Mental state: Not improved (paranoid distortion) Multidimentional Scale for Rating Psychiatric Patients (short term) · patients with schizophrenia
It is very uncertain whether CHLORPROMAZINE changes mental state: Not improved (paranoid distortion) Multidimentional… compared with RESERPINE (very low certainty).
1 finding from 1 review
Functioning: not improved occupational adjustment (short term) · patients with schizophrenia
CHLORPROMAZINE showed no clear difference in functioning: not improved occupational adjustment (short term) compared with RESERPINE (moderate certainty).
1 finding from 1 review
Adverse events ‐ toxic reaction (short term) · patients with schizophrenia
CHLORPROMAZINE showed no clear difference in adverse events ‐ toxic reaction (short term) compared with RESERPINE (moderate certainty).
1 finding from 1 review
Leaving the study early ‐ due to adverse effects (short term) · patients with schizophrenia
CHLORPROMAZINE showed no clear difference in leaving the study early ‐ due to adverse effects (short term) compared with RESERPINE (moderate certainty).
1 finding from 1 review
Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · Patients with acute low‐back pain
1 finding from 1 review
Disability 1 week (immediate term) (RMDQ 0 to 24) · Patients with acute low‐back pain
1 finding from 1 review
Change in pain intensity from baseline on VAS (0 to 100) short‐term · people with low back pain with sciatica
It is very uncertain whether NSAIDs changes change in pain intensity from baseline on VAS (0 to 100) short‐term compared with placebo (very low certainty).
1 finding from 1 review
Global Improvement short‐term · people with low back pain with sciatica
NSAIDs may leads to higher global Improvement short‐term compared with placebo (low certainty).
1 finding from 1 review
Side effects short‐term · people with low back pain with sciatica
NSAIDs may leads to higher side effects short‐term compared with placebo (low certainty).
1 finding from 1 review
Occlusion (change in maxillary arch length, short term) · Children with a non-nutritive sucking habit (digit or pacifier)
1 finding from 1 review
Table 1 (reduction in malocclusion), Villa 1997 (n=24), palatal crib vs no treatment: change in maxillary arch length (mm) - no treatment 0.01 (SD 0.33); palatal crib -1.4 (SD 1.4); reported as statistically…
1 study · 24 participants
GRADE not reported
Sucking cessation (short term) · Children with a non-nutritive sucking habit (digit or pacifier)
It is very uncertain whether palatal arch changes sucking cessation (short term) compared with palatal crib (alternative orthodontic appliance) (very low certainty).
1 finding from 1 review